Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

RATIONALE: An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care. OBJECTIVES: To evaluate the safety and immunogenicity of a leading new TB vaccine, recombinant Modified Vaccinia Ankara expressing Anti...

Full description

Bibliographic Details
Main Authors:	Sander, C, Pathan, A, Beveridge, N, Poulton, I, Minassian, A, Alder, N, Van Wijgerden, J, Hill, A, Gleeson, F, Davies, R, Pasvol, G, Mcshane, H
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
by: Sander, C, et al.
Published: (2005)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
by: Griffiths, K, et al.
Published: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
by: Griffiths, K, et al.
Published: (2011)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Whelan, K, et al.
Published: (2009)

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
by: Beveridge, N, et al.
Published: (2007)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
by: Kristin L Griffiths, et al.
Published: (2011-01-01)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
by: Rowland, R, et al.
Published: (2012)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
by: Mcshane, H, et al.
Published: (2005)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
by: Pathan, A, et al.
Published: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
by: Pathan, A, et al.
Published: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Brookes, R, et al.
Published: (2008)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
by: de Cassan, S, et al.
Published: (2010)

CD4 T cell response to MVA85A vaccination against Mycobacterium tuberculosis in healthy HIV-infected adults
by: Beveridge, N, et al.
Published: (2011)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Roger H Brookes, et al.
Published: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
by: Roger H. Brookes, et al.
Published: (2011-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)

Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (vol 17, pg 1066, 2010)
by: de Cassan, S, et al.
Published: (2011)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG immunized adults vaccinated with a new tuberculosis vaccine, MVA85A (Clinical and Vaccine Immunology (2010) 17, 7, (1066-1073))
by: De Cassan, S, et al.
Published: (2011)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
by: Rowland, R, et al.
Published: (2013)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
by: Hawkridge, T, et al.
Published: (2008)

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
by: Scriba, T, et al.
Published: (2012)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
by: Ota, M, et al.
Published: (2011)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
by: Fletcher, H, et al.
Published: (2008)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
by: Ota, M, et al.
Published: (2011)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
by: White, A, et al.
Published: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
by: Minassian, A, et al.
Published: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Published: (2011-01-01)

Th1/Th17 cell induction following vaccination with the novel tuberculosis vaccine MVA85A and their role in Mycobacterium tuberculosis challenge
by: Griffiths, K, et al.
Published: (2011)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
by: Mcshane, H, et al.
Published: (2016)

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guérin
by: Minassian, A, et al.
Published: (2012)

A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.
by: Minassian, A, et al.
Published: (2012)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
by: Ibanga, H, et al.
Published: (2006)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
by: Harris, SA, et al.
Published: (2014)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Pathan, A, et al.
Published: (2007)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
by: Minhinnick, A, et al.
Published: (2016)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Pathan, A, et al.
Published: (2007)

Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells.
by: Lalvani, A, et al.
Published: (2001)

Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
by: Tchilian, E, et al.
Published: (2009)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
by: Scriba, T, et al.
Published: (2011)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
by: Gilbert, S, et al.
Published: (2006)